*Based on a retrospective analysis of VNS Therapy™ titration and dosing practice that compiled patient data from 12 clinical studies. Analysis includes randomized controlled trials and open-label observational studies. Clinical response was defined as a reduction in seizure frequency from baseline of 50% or greater2.
The Right Dose at The Right Time
Aligning clinical practice to increase chances to achieve a therapeutic response in your patients
Key Dosing Parameters
Together, output current, pulse width, and signal frequency can be considered the dose of VNS Therapy. Duty cycle can be regarded as dosing frequency.
Output current and pulse width comprises the target volume whereas signal frequency and duty cycle can be considered as the therapeutic neural modulation ‘message’ for VNS Therapy.
Patients implanted and dosed shortly after their initial DRE diagnosis were shown to benefit from VNS Therapy. However, chronically underdosed patients currently on VNS Therapy may still benefit from target-range titration.2
Key considerations during dosing to improve patient outcomes*
Reach the target range for dosing
Consider the target dose combination for DRE patients as3:
Use rapid titration
Patients who were titrated to target within 3 months according to the recommended protocol achieve onset of response faster.1,3
Side effects for VNS Therapy™ in DRE patients may be similar regardless of the speed of titration schedule.1 Adjust settings as needed to ensure tolerability as patients habituate to stimulation.
Achieving a therapeutic response is key to improve patient outcomes. Explore a range of resources to support you in the dosing prcoess.
The Right Dose at The Right Time
The Right Dose at The Right Time
VNS Therapy™ Parameters for Clinical Response
Rapid Titration Reduces Time-To-Response
Dosing Guidelines - SenTiva™, SenTiva™ Duo
Dosing Guidelines - Other Models
